A randomized trial of memantine as treatment for spasticity in multiple sclerosis


Summary

Small study reports the results of a single center randomized, double-blind, placebo-controlled, parallel group trial of memantine in adults with multiple sclerosis. Mult Scler. 2009 Dec 22


Details

Small study reports the results of a single center randomized, double-blind, placebo-controlled, parallel group trial of memantine in adults with multiple sclerosis and spasticity conducted over 12 weeks. Eligible MS patients were required to have an Ashworth spasticity rating of 2 or higher in at least one lower extremity muscle group.

Twenty-one subjects were randomized to receive either placebo

(ten) or memantine (11) 10 mg twice a day. The primary outcome

measure of efficacy was a change in Ashworth Spasticity Scale

Score. Although well tolerated, memantine treatment did not

demonstrate efficacy in treatment of spasticity in this 12-week

small exploratory study.



National Research and Programs